QQ客服 官方微博 反馈留言

	Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer
	Wu, Yi-Long; Lu, Shun; Lu, You; Zhou, Jianying; Shi, Yuan-kai; Sriuranpong, Virote; Ho, James C. M.; Ong, Choo Khoon; Tsai, Chun-Ming; Chung, Chin-Hee
	2018
卷号	13期号:10页码:1539-1548
关键词	ALK-positive advanced non-small cell lung cancer crizotinib chemotherapy phase III
ISSN号	1556-0864
DOI	10.1016/j.jtho.2018.06.012
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6358411
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Wu, Yi-Long,Lu, Shun,Lu, You,et al. Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer[J],2018,13(10):1539-1548.
APA	Wu, Yi-Long.,Lu, Shun.,Lu, You.,Zhou, Jianying.,Shi, Yuan-kai.,...&Mok, Tony S..(2018).Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer.,13(10),1539-1548.
MLA	Wu, Yi-Long,et al."Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer".13.10(2018):1539-1548.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。